AP
Therapeutic Areas
BetaGlue Therapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| YntraDose | Unresectable Locally Advanced Pancreatic Ductal Adenocarcinoma (uLA-PDAC) | Phase 1 |
Leadership Team at BetaGlue Therapeutics
SC
Salvatore Calabrese
Chief Financial Officer (CFO)
DG
Dr. Gianluca De Danieli
Head of Clinical Development
GB
Gaia Bisaccioni
Head of RA/QA
PB
Pietro Bubba Bello
Head of Manufacturing & Operations
DP
Dr. Pieter Janssen
Head of Product Development
DC
Dr. Carol Hegarty
Head of Clinical Operations